CatalystMarker
← board

HYFT

distress 5/10 · elevated risk
$1.26-12%today-61% from 52w high
mindwalkai.com81 employeesFounded 1983Austin, TXBiotechnology
Revenue
pre-revenue
Liquidity
$14M
Runway
2.2 yrs
Shares 1y
+141%

Price & events

-45.2% over 6M
$1.02$1.66$2.30Jan 26Apr 26Jul 263.3Mdilution: F-3 shelf_registration (2026-07-13)rating: HC Wainwright & Co.: Buy (2026-05-19)rating: Jones Trading: Buy (2026-04-16)
CatalystRating changeDilutionFinancingdashed = today
-12.5%
1D
-10.6%
1W
-15.4%
1M
+5.0%
3M
-44.5%
6M
-30.8%
1Y
+48.4%
2Y
-85.2%
5Y
-90.6%
All

Overview

Market Cap
$58.15M
Volume
288.57K
52 Week Range
$1.02 – $3.20
Total Shares
46.15M
Float Shares
45.37M
Short %
1.85%
% Held by Insiders
9.02%
% Held by Institutions
9.99%
RVOL
1.06x
Beta
0.83

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 1

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 46,711,866 · 1 offerings/1y · 0 PIPEs
  • 2026-07-13F-3shelf_registration
  • 2025-11-07424B5offering
  • 2024-08-16EFFECTshelf_effective
  • 2024-08-06F-3shelf_registration
  • 2024-07-30424B5offering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $4 (+244% upside) · 3 analysts
  • 2026-05-19HC Wainwright & Co.Buy
  • 2026-04-16Jones TradingBuy

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.